Bragar Eagel & Squire, P.C. Is Investigating RBC, Intuit, Rollins, and PROG and Encourages Investors to Contact the Firm
September 06, 2022 21:08 ET
|
Bragar Eagel & Squire
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against RBC Bearings Incorporated...
Progenity Announces Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
January 11, 2022 06:30 ET
|
Progenity, Inc.
SAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Announces Acceptance of Two Abstracts on Treatment of Gastrointestinal Disorders at ECCO’22
January 05, 2022 06:30 ET
|
Progenity, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
January 03, 2022 06:30 ET
|
Progenity, Inc.
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Completes Exit from Laboratory Business with Sale of Affiliate Lab
December 20, 2021 16:05 ET
|
Progenity, Inc.
SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Announces New Patent for Single-Molecule Detection Technology
December 02, 2021 06:30 ET
|
Progenity, Inc.
SAN DIEGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics, today announced a...
Progenity Strengthens its Liquidity Position
November 23, 2021 06:30 ET
|
Progenity, Inc.
Company received more than $44 million in warrant exercises since August 2021. Current liquidity position provides runway to achieve critical research and development milestones through 2022. SAN...
Progenity to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 15, 2021 06:30 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that the company will participate in a pre-recorded fireside chat at...
Progenity Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 10, 2021 16:01 ET
|
Progenity, Inc.
Added important patents further protecting the company’s therapeutic delivery technologiesAdded strong biotherapeutics capabilities to management team and board of directorsImplemented cost-cutting...
Progenity Appoints Adi Mohanty as Chief Executive Officer
November 09, 2021 06:30 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Adi Mohanty as Chief Executive Officer of the...